The 18-Month MDR-TB Regimen Has a Successor - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The 18-Month MDR-TB Regimen Has a Successor

Six months, all-oral, better tolerated—and the infrastructure to make it work.

  • By

  • Kerri Miller

  • April 16, 2026

  • 3 min

Share

  • 1

    Pretomanid prescribing in NHS England increased fivefold from early 2024 to 2025, reflecting successful implementation of shorter MDR-TB regimens.

  • 2

    Evidence supports 6 to 9 month bedaquiline-based regimens, showing favorable outcomes of 84% to 93% across various trial populations.

  • 3

    Implementation in the UK involved expert oversight, a funded access pathway, and drug-specific monitoring to ensure safe prescribing.

  • 4

    Shorter regimens reduce pill burden and adverse events, improving adherence and freeing clinical capacity for healthcare providers.

  • 5

    The UK model illustrates necessary system design for safe and equitable MDR-TB treatment, despite limitations in drug safety monitoring.

Original Source(s)

The 18-Month MDR-TB Regimen Has a Successor

  • by Kerri Miller

  • April 16, 2026

Related Content

Shorter TB Regimens Advance Care

Review highlights shorter tuberculosis regimens while warning that rising bedaquiline resistance may threaten future progress.

Early ICU Rehab Backed, With Caveats

Invited narrative review supports early, interprofessional rehabilitation across the ICU recovery continuum while emphasizing heterogeneous evidence and inconsistent implementation worldwide.

Postextubation Pneumonia Tops Ventilator Pneumonia

Older age, male sex, underweight status, reduced activities of daily living, and mild consciousness disturbance were associated with postextubation pneumonia in elective surgical patients.